Rep. Thomas H. Kean, Jr. Sells Johnson & Johnson (NYSE:JNJ) Stock

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on April 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on March 26th. The trade occurred in the Representative’s “STATE STREET BANK & TRUST CO.” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 3/31/2026.
• Purchased $1,001 – $15,000 in shares of Linde (NASDAQ:LIN) on 3/26/2026.
• Sold $15,001 – $50,000 in shares of PepsiCo (NASDAQ:PEP) on 3/26/2026.
• Sold $1,001 – $15,000 in shares of First Citizens BancShares (NASDAQ:FCNCA) on 3/26/2026.
• Sold $15,001 – $50,000 in shares of Chubb (NYSE:CB) on 3/26/2026.
• Sold $15,001 – $50,000 in shares of S&P Global (NYSE:SPGI) on 3/26/2026.
• Sold $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 3/10/2026.
• Purchased $1,001 – $15,000 in shares of Linde (NASDAQ:LIN) on 2/18/2026.
• Sold $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 2/13/2026.
• Purchased $1,001 – $15,000 in shares of First Citizens BancShares (NASDAQ:FCNCA) on 2/5/2026.

Johnson & Johnson Stock Up 0.9%

JNJ stock opened at $240.14 on Wednesday. The firm has a 50-day moving average price of $241.58 and a 200-day moving average price of $216.38. Johnson & Johnson has a 12 month low of $146.12 and a 12 month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $578.40 billion, a P/E ratio of 21.73, a price-to-earnings-growth ratio of 2.37 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Stockholders of record on Tuesday, May 26th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

Analyst Ratings Changes

Several research analysts have recently issued reports on JNJ shares. Scotiabank reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Daiwa Securities Group boosted their price objective on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a report on Wednesday, January 28th. Guggenheim increased their target price on Johnson & Johnson from $240.00 to $244.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. Finally, Barclays lifted their price target on Johnson & Johnson from $217.00 to $234.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $238.17.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 22,623 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares in the company, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 30,142 shares of company stock worth $7,360,528. 0.16% of the stock is owned by insiders.

Institutional Trading of Johnson & Johnson

Several institutional investors have recently modified their holdings of JNJ. J. Derek Lewis & Associates Inc. acquired a new stake in Johnson & Johnson in the fourth quarter valued at $296,000. Purpose Unlimited Inc. acquired a new position in Johnson & Johnson during the 4th quarter worth about $131,000. Cornerstone Planning LLC acquired a new position in Johnson & Johnson during the 4th quarter worth about $4,442,000. Rockefeller Capital Management L.P. grew its position in shares of Johnson & Johnson by 12.7% in the 4th quarter. Rockefeller Capital Management L.P. now owns 937,751 shares of the company’s stock valued at $194,068,000 after buying an additional 105,383 shares during the last quarter. Finally, Bank of New Hampshire increased its stake in shares of Johnson & Johnson by 4.8% in the fourth quarter. Bank of New Hampshire now owns 14,480 shares of the company’s stock valued at $2,997,000 after buying an additional 660 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Q1 beat and raised FY guidance — J&J reported Q1 revenue of $24.06B and EPS of $2.70 (above estimates) and updated FY26 EPS guidance to the mid‑range (~$11.45–11.65) while nudging revenue targets higher, which underpins today’s bullish move. Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
• Positive Sentiment: Dividend raise — the board increased the quarterly payout to $1.34 (3.1% increase), marking J&J’s 64th consecutive annual increase; this strengthens the stock’s appeal to income investors. Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
• Positive Sentiment: Product momentum — strong sales for oncology drug Darzalex, Tremfya and faster‑growing Spravato (esketamine) support top‑line strength and helped offset other weakness. J&J’s first-quarter profit beats estimates even as Stelara sales disappoint
• Neutral Sentiment: Analyst and market reaction is mixed — several bullish writeups and a raised price target contrast with cautious notes about the guidance nuance; this is supporting constructive but measured investor interest. Johnson & Johnson Price Target Raised to $267.00
• Neutral Sentiment: Broader sector signal — J&J’s beat is being read as a positive indicator for healthcare ETFs and peers, so flows into the sector may influence JNJ momentum. What Johnson & Johnson Earnings Signal for Healthcare ETFs
• Negative Sentiment: Stelara decline and cash‑flow softness — a steep drop in Stelara sales and a reported fall in free cash flow are offsets investors are watching; these were cited as reasons for an early intraday pullback in some coverage. Johnson & Johnson Q1 Performance: Cancer Drug Revenue Grows, Free Cash Flow Falls, Hikes Dividend
• Negative Sentiment: Guidance nuance — some outlets flagged the sales/growth outlook as modest versus high investor expectations, which can cap upside until the company proves sustained acceleration. Johnson & Johnson Earnings: JNJ Stock Slips on Modest 2026 Sales Forecast despite Q1 Beat

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.